Display options
Cite
Mussi-Pinhata MM, Ward S, Laimon L, et al. Effect of Maternal Vaccination of PCV-10, PPV-23 or Placebo on the Immunogenicity of PCV-10 in HIV-exposed Uninfected Infants: A Randomized Clinical Trial. Clin Infect Dis. 2022;doi: 10.1093/cid/ciac026.
Mussi-Pinhata, M. M., Ward, S., Laimon, L., Pelton, S. I., Canniff, J., Golner, A., Bone, F., Newton, L., Muresan, P., Fenton, T., Johnson, M. J., João, E. C., Santos, B. R., Pilotto, J. H., Oliveira, R. H., Pinto, J. A., Dal Bó, A. G. B. L., Kreitchmann, R., Chakhtoura, N., Duarte, G., Weinberg, A. (2022). Effect of Maternal Vaccination of PCV-10, PPV-23 or Placebo on the Immunogenicity of PCV-10 in HIV-exposed Uninfected Infants: A Randomized Clinical Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, . https://doi.org/10.1093/cid/ciac026
Mussi-Pinhata, Marisa M, et al. "Effect of Maternal Vaccination of PCV-10, PPV-23 or Placebo on the Immunogenicity of PCV-10 in HIV-exposed Uninfected Infants: A Randomized Clinical Trial." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America vol. (2022). doi: https://doi.org/10.1093/cid/ciac026
Mussi-Pinhata MM, Ward S, Laimon L, Pelton SI, Canniff J, Golner A, Bone F, Newton L, Muresan P, Fenton T, Johnson MJ, João EC, Santos BR, Pilotto JH, Oliveira RH, Pinto JA, Dal Bó AGBL, Kreitchmann R, Chakhtoura N, Duarte G, Weinberg A. Effect of Maternal Vaccination of PCV-10, PPV-23 or Placebo on the Immunogenicity of PCV-10 in HIV-exposed Uninfected Infants: A Randomized Clinical Trial. Clin Infect Dis. 2022 Jan 17; doi: 10.1093/cid/ciac026. Epub 2022 Jan 17. PMID: 35037049.
Copy Download .nbib Format: NLM
Share it on

Clin Infect Dis. 2022 Jan 17; doi: 10.1093/cid/ciac026. Epub 2022 Jan 17.

Effect of Maternal Vaccination of PCV-10, PPV-23 or Placebo on the Immunogenicity of PCV-10 in HIV-exposed Uninfected Infants: A Randomized Clinical Trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Marisa M Mussi-Pinhata, Shawn Ward, Lauren Laimon, Stephen I Pelton, Jennifer Canniff, Amanda Golner, Frederic Bone, Lassallete Newton, Petronella Muresan, Terence Fenton, Michael J Johnson, Esau C João, Breno R Santos, Jose H Pilotto, Ricardo H Oliveira, Jorge A Pinto, Andrea G B L Dal Bó, Regis Kreitchmann, Nahida Chakhtoura, Geraldo Duarte, Adriana Weinberg,

Affiliations

  1. Ribeirão Preto Medical School, University of São Paulo, Brazil.
  2. Frontier Science Foundation, Brookline, MA, USA.
  3. Westat, Rockville, MD, USA.
  4. Boston University School of Medicine, Boston, MA, USA.
  5. Colorado University Anschutz Medical Campus, Aurora, CO, USA.
  6. Frontier Science Foundation, Buffalo, NY, USA.
  7. Hospital Federal dos Servidores do Estado, Rio de Janeiro, RJ, Brazil.
  8. Hospital Nossa Senhora da Conceição, Porto Alegre, RGS, Brazil.
  9. Hospital Geral de Nova Iguaçu & Laboratório de AIDS e Imunologia Molecular - Fiocruz, Rio de Janeiro, Brazil.
  10. Instituto de Puericultura e Pediatra Matagão Gesteira, Rio de Janeiro, RJ, Brazil.
  11. School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.
  12. Health Research Institute, University of Caxias do Sul, Brazil.
  13. Federal University of Health Sciences of Porto Alegre, Brazil.
  14. Eunice Kennedy Shriver National Institute of Child Health & Human Development, Bethesda, MD, USA.

PMID: 35037049 DOI: 10.1093/cid/ciac026

Abstract

BACKGROUND: The effect of pneumococcal vaccination of mothers with HIV on infant responses to childhood vaccination has not been studied. We compared the immunogenicity of PCV-10 in HIV-exposed uninfected infants born to mothers who received PCV-10, PPV-23 or placebo during pregnancy.

METHODS: Antibody levels against seven serotypes were measured at birth, before the 1 st and 2 nd doses of PCV-10 and after the completion of the 2-dose regimen in 347 infants, including 112 born to mothers who received PPV-23, 112 PCV-10, and 119 placebo during pregnancy. Seroprotection was defined by antibody levels ≥0.35µg/ml.

RESULTS: At birth and 8 weeks of life, antibody levels were similar in infants born to PCV-10- or PPV-23-recipient mothers and higher than infants of placebo-recipient mothers. After the last dose of PCV-10, infants in the maternal PCV-10 group had significantly lower antibody levels against five serotypes compared to infants in the maternal PPV-23 group; against three serotypes compared to infants in the maternal placebo group; and did not have higher antibody levels against any serotype. The seroprotection rate against seven serotypes was 50% in infants in the maternal PCV-10 compared to 71% in each of the maternal PPV-23 and placebo groups (p<0.0001).

CONCLUSIONS: Administration of PCV-10 during pregnancy was associated with decreased antibody responses to PCV-10 and seroprotection rates in infants. Considering that PCV-10 and PPV-23 had similar immunogenicity in pregnant women with HIV and that administration of PPV-23 did not affect the immunogenicity of PCV-10 in infants, PPV-23 in pregnancy may be preferred over PCV-10.

© The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: [email protected].

Keywords: HIV infection; infant; maternal immunization; pneumococcal vaccine; vaccine immunogenicity

Publication Types